Redeye notes a weak Q2 for Sedana Medical, with lower sales and higher costs than we expected. Still, other direct markets (excl., Germany) developed well and are an important metric to better understand its US prospects, which will be a main focus area going forward as the clinical trials have been fully recruited and are now awaiting data to be presented.